journal logo
  • search
  • open the menu

Journal for ImmunoTherapy of Cancer

Intro Widget

The Journal for ImmunoTherapy of Cancer (JITC) is the open access, peer reviewed journal that publishes on all aspects of tumor immunology and cancer immunotherapy, aiming to enrich communication and advance scientific understanding in this rapidly evolving field. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.

As a way to say thank you to the dedicated Society for Immunotherapy of Cancer (SITC) members who tirelessly work to advance the science and improve the lives of patients with cancer, SITC will provide members with a 50% discount on article processing charges for all member-authored 2020 publications.

COVID-19: A Message from BMJ

Impact Factor
8.728

New JITC Collections

Within JITC's full catalog of published articles, a number of collections are available to provide readers with opportunities to view sets of papers following particular themes. The two newest collections that continue to receive new publications include the Immune Checkpoints Beyond PD-1 Review Series and the COVID-19 Collection.

Altmetrics

About SITC

The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.

 

Learn more about the SITC’s mission and explore the cancer immunotherapy community at SITC Cancer Immunotherapy CONNECT.